Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies [0.03%]
托珠单抗低剂量用于T细胞衔接双特异性抗体引起的细胞因子释放综合征的治疗
Issam S Hamadeh,Maximillian Merz,Andriy Derkach et al.
Issam S Hamadeh et al.
Background: Cytokine release syndrome (CRS) is one of the most common adverse effects of T-cell engaging bispecific antibodies (T-BsAbs) during the step-up dosing (SUD) phase of treatment. Previous studies demonstrated th...
Implementing Next-Generation Sequencing (NGS) in Resource-Constrained Settings: The Experience of the International Consortium on Acute Leukemias (ICAL) [0.03%]
新一代测序技术（NGS）在资源有限环境中的实施：国际急性白血病联盟的实践经验
Rita de Cássia Cavaglieri,Luciana Nardinelli,Melissa Rijken et al.
Rita de Cássia Cavaglieri et al.
Next-generation sequencing (NGS) has transformed the diagnostic and prognostic landscape of acute myeloid leukemia (AML) by enabling the simultaneous detection of multiple clinically relevant mutations. However, access to this technology re...
SOHO State of the Art Updates and Next Questions | Peripheral T-Cell Lymphoma: Current Landscape and Emerging Questions [0.03%]
SOHO最新研究进展和下一步问题 | 外周T细胞淋巴瘤：当前格局与未来展望
Seda S Tolu,Barbara Pro
Seda S Tolu
Peripheral T-cell lymphomas (PTCLs) comprise a rare, heterogeneous group of mature T-cell and NK-cell neoplasms, representing approximately 10% to 15% of all non-Hodgkin lymphomas. Despite advances in disease classification and biology, cli...
Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell Disorders [0.03%]
多发性骨髓瘤和前体浆细胞疾病的患者的诊断披露及其相关疾病体验
Maria A Malik,Akshay A Dalvi,Andriy Derkach et al.
Maria A Malik et al.
Background: Social support is associated with improved prognosis and quality of life after a cancer diagnosis. However, less is known about patients' experiences with disclosing their diagnosis to access support. This stu...
Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review [0.03%]
系统评价：渐变型多发性骨髓瘤临床试验生活质量的测量：系统性综述
José Emiliano Montelongo-Cepeda,Sofía I Quezada-Ramírez,Hector A Vaquera Alfaro et al.
José Emiliano Montelongo-Cepeda et al.
The therapeutic approach to smoldering multiple myeloma (SMM) is shifting from observation to early treatment, particularly in patients at high-risk of progression. Patients with SMM may experience factors that can negatively affect health-...
Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia [0.03%]
为期7天的Venetoclax联合强化调整剂量化疗作为新诊断急性髓系白血病诱导治疗方案的研究
Ting Liu,Xingli Zhao,Xiaohui Suo et al.
Ting Liu et al.
While venetoclax (VEN) combined with intensive chemotherapy (IC) has demonstrated efficacy in newly diagnosed acute myeloid leukemia (AML), the optimal duration of VEN administration remains uncertain, leading to variability in its applicat...
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas [0.03%]
中国复发/难治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤及其他非霍奇金淋巴瘤患者中BCL-2抑制剂ABR-217020（APG-2575）I期临床试验
Mingyuan Sun,Keshu Zhou,Junyuan Qi et al.
Mingyuan Sun et al.
Background: Lisaftoclax is a novel BCL-2 inhibitor. This phase 1 trial (NCT03913949) evaluated the safety and preliminary efficacy of lisaftoclax in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leuk...
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial [0.03%]
HD21试验中晚期经典霍奇金淋巴瘤患者对多药化疗方案诱导的周围神经病变(CIPN)的看法
Fjoralba Kristo,Flora Mazerolle,Thibaud Alin et al.
Fjoralba Kristo et al.
Introduction: Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymph...
Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study [0.03%]
西班牙多发性骨髓瘤患者管理的当前常规临床实践描述性研究：CROMMAS 研究
Enrique M Ocio,María-Victoria Mateos;CROMMAS Study Group
Enrique M Ocio
Background: The therapeutic landscape of multiple myeloma (MM) has evolved substantially in recent years, with expanding treatment options and increasing complexity in managing both newly diagnosed and relapsed/refractory...
Comparison of Patient-Reported Outcomes for Elranatamab in MagnetisMM-3 Versus Real-World Physician Choice of Therapy for Triple-Class Refractory Multiple Myeloma [0.03%]
ELRANATAMAB MagnetisMM-3研究患者报告结果与真实世界三线后治疗的比较分析
Benjamin Hebraud,Charis Charalampous,Ricardo Parrondo et al.
Benjamin Hebraud et al.
Background: Multiple myeloma (MM) impairs function and quality of life, which can be impacted by treatment choices. We compared patient-reported outcomes (PROs) in triple-class refractory (TCR) MM between patients treated...